The differential ability of human IgG1 and IgG4 to activate complement is determined by the COOH-terminal sequence of the CH2 domain

doi:10.1084/jem.173.4.1025

This Article

	Full Text (PDF, 417K)
	Alert me when this article is cited
	Citation Map

Services

	Email this article
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new content in the JEM
	Download to citation manager

Citing Articles

	Citing Articles via HighWire
	Citing Articles via CrossRef
	Citing Articles via Google Scholar

Google Scholar

	Articles by Tao, M. H.
	Articles by Morrison, S. L.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Tao, M. H.
	Articles by Morrison, S. L.


Social Bookmarking

	What's this?

ARTICLES

The differential ability of human IgG1 and IgG4 to activate complement is determined by the COOH-terminal sequence of the CH2 domain

MH Tao, SM Canfield and SL Morrison
Department of Microbiology, College of Physicians and Surgeons, Columbia University, New York, New York 10032.

Using domain switch chimeric antibodies, we confirm the important role of CH2 in complement activation. In addition, we demonstrate that the structures responsible for the differential ability of human IgG1 and IgG4 to activate complement are located at the COOH-terminal part (from residue 292 to 340) of the CH2 domain. The amino acids in CH2 that might be involved in complement interaction are discussed. While CH3 contributes to efficient complement activation, CH3 from IgG2 and CH3 IgG3 are equally effective.
Add to CiteULike CiteULike Add to Complore Complore Add to Connotea Connotea Add to Del.icio.us Del.icio.us Add to Digg Digg Add to Reddit Reddit Add to Technorati Technorati What's this?

This article has been cited by other articles:

Natsume, A., In, M., Takamura, H., Nakagawa, T., Shimizu, Y., Kitajima, K., Wakitani, M., Ohta, S., Satoh, M., Shitara, K., Niwa, R. (2008). Engineered Antibodies of IgG1/IgG3 Mixed Isotype with Enhanced Cytotoxic Activities. Cancer Res. 68: 3863-3872 [Abstract] [Full Text]
Lu, Y., Harding, S. E., Michaelsen, T. E., Longman, E., Davis, K. G., Ortega, A., Grossmann, J. G., Sandlie, I., Garcia de la Torre, J. (2007). Solution Conformation of Wild-Type and Mutant IgG3 and IgG4 Immunoglobulins Using Crystallohydrodynamics: Possible Implications for Complement Activation. Biophys. J 93: 3733-3744 [Abstract] [Full Text]
Montano, R. F., Morrison, S. L. (2002). Influence of the Isotype of the Light Chain on the Properties of IgG. J. Immunol. 168: 224-231 [Abstract] [Full Text]
Idusogie, E. E., Presta, L. G., Gazzano-Santoro, H., Totpal, K., Wong, P. Y., Ultsch, M., Meng, Y. G., Mulkerrin, M. G. (2000). Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc. J. Immunol. 164: 4178-4184 [Abstract] [Full Text]
Guan, L., Wims, L. A., Kane, R. R., Smuckler, M. B., Morrison, S. L., Hawthorne, M. F. (1998). Homogeneous immunoconjugates for boron neutron-capture therapy: Design, synthesis, and preliminary characterization. Proc. Natl. Acad. Sci. USA 95: 13206-13210 [Abstract] [Full Text]
Isaacs, J. D., Greenwood, J., Waldmann, H. (1998). Therapy with Monoclonal Antibodies. II. The Contribution of Fc{gamma} Receptor Binding and the Influence of CH1 and CH3 Domains on In Vivo Effector Function. J. Immunol. 161: 3862-3869 [Abstract] [Full Text]
Kozlowski, L. M., Li, W., Goldschmidt, M., Levinson, A. I. (1998). In Vivo Inflammatory Response to a Prototypic B Cell Superantigen: Elicitation of an Arthus Reaction by Staphylococcal Protein A. J. Immunol. 160: 5246-5252 [Abstract] [Full Text]
Morrison, S. L., Porter, S. B., Trinh, K. R., Wims, L. A., Denham, J., Oi, V. T. (1998). Variable Region Domain Exchange Influences the Functional Properties of IgG. J. Immunol. 160: 2802-2808 [Abstract] [Full Text]
Poon, P. H., Morrison, S. L., Schumaker, V. N. (1995). Structure and Function of Several Anti-Dansyl Chimeric Antibodies Formed by Domain Interchanges between Human IgM and Mouse IgG2b. J. Biol. Chem. 270: 8571-8577 [Abstract] [Full Text]